Join Growin Stock Community!

國光生4142.TW Overview

TW StockBiotech. & Medical
(No presentation for 4142)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

國光生（4142）Overall Performance

國光生（4142）AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

國光生（4142） PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

國光生（4142）Key Information

國光生（4142）Profile

Adimmune Corporation manufactures and sells human vaccines in Taiwan. It offers AdimFlu-S, a quadrivalent influenza vaccine; tetanus toxoid alum precipitated product that is used for the prevention of tetanus after injury; Japanese encephalitis vaccines; Trivalent influenza vaccines; Quadrivalent influenza vaccine; Influenza A (H1N1) Virus Monovalent Vaccine; Tetanus Toxoid; and purified Tuberculin, as well as contract manufacturing services. The company was formerly known as Kuo Kwang Serum and Vaccine Manufacture Co., Ltd. and changed its name to Adimmune Corporation in 2001. Adimmune Corporation was founded in 1965 and is headquartered in Taichung, Taiwan.

國光生（4142）FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

4142.TW logo

4142

國光生

17.80D

-1.12%

(-0.01)

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.18
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
6.37
PB Ratio
1.58
Price-to-FCF
19.34
METRIC
VALUE
vs. INDUSTRY
Gross Margin
2.67%
Net Margin
-42.34%
Revenue Growth (YoY)
-23.56%
Profit Growth (YoY)
-92.28%
3-Year Revenue Growth
-24.10%
3-Year Profit Growth
-46.64%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.18
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
6.37
PB Ratio
1.58
Price-to-FCF
19.34
Gross Margin
2.67%
Net Margin
-42.34%
Revenue Growth (YoY)
-23.56%
Profit Growth (YoY)
-92.28%
3-Year Revenue Growth
-24.10%
3-Year Profit Growth
-46.64%

  • When is 4142's latest earnings report released?

    The most recent financial report for 國光生 (4142) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 4142's short-term business performance and financial health. For the latest updates on 4142's earnings releases, visit this page regularly.

  • What is the operating profit of 4142?

    According to the latest financial report, 國光生 (4142) reported an Operating Profit of -60.2M with an Operating Margin of -12.67% this period, representing a decline of 122.4% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is 4142's revenue growth?

    In the latest financial report, 國光生 (4142) announced revenue of 475.32M, with a Year-Over-Year growth rate of -46.49%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does 4142 have?

    At the end of the period, 國光生 (4142) held Total Cash and Cash Equivalents of 1.76B, accounting for 0.21 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does 4142 go with three margins increasing?

    In the latest report, 國光生 (4142) did not achieve the “three margins increasing” benchmark, with a gross margin of 17.76%%, operating margin of -12.67%%, and net margin of -8.11%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 4142's profit trajectory and future growth potential.

  • Is 4142's EPS continuing to grow?

    According to the past four quarterly reports, 國光生 (4142)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.04. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of 4142?

    國光生 (4142)'s Free Cash Flow (FCF) for the period is 60.6M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 52.1% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.